Search for a command to run...
<h3>Background and Importance</h3> Elderly individuals constitute a significant percentage of patients with malignant haematological diseases, a proportion anticipated to increase due to population ageing and the emergence of novel therapeutic targets that manage and chronify the disease. These patients frequently present with cognitive impairment, malnutrition, physical dependency, and polypharmacy, necessitating a comprehensive, multidisciplinary approach. <h3>Aim and Objectives</h3> To design a specialised pharmaceutical care model for the geriatric haemato-oncology patient and evaluate its clinical outcomes. <h3>Material and Methods</h3> A prospective observational study was conducted from March 2023 to September 2025 within the Pharmaceutical Care Consultation for oncohaematology patients at a primary care hospital. The haematologist selected the frailest patients, identified using the G8 scale and those with the highest number of comorbidities (assessed via the CIRS-G scale), referring them to the Pharmacy consultation. The dedicated pharmacist performed a pre-evaluation of home medication, self-medication, and alternative medicine. This screening aimed to detect drug interactions, therapeutic duplications, inappropriately prescribed medications (using the STOPP-START criteria), assess for potential deprescribing of polypharmacy, and evaluate adherence via the Morisky-Green Test. If any errors in medication intake, interactions, or adverse drug reactions were detected, pharmaceutical interventions were formally documented in the patient‘s Clinical History. <h3>Results</h3> The new working model provided care for 49 patients (median age 80 years; 64% male, 36% female). Adherence to haemato-oncology treatment was successfully improved in 90% of the patients. A total of 31 pharmaceutical interventions were performed: Four related to dosage or administration method. Eight concerning pharmacological interactions that required substituting a medication. Five due to therapeutic duplications. Six regarding interacting herbal products or multivitamin complexes. Three due to failure to attend a medical review in 2 years. Five involving the prescription of medications with low therapeutic value and high anticholinergic burden, which were subsequently suspended. <h3>Conclusion and Relevance</h3> The hospital pharmacist plays a crucial and significant role in the pharmaceutical care of the geriatric haemato-oncology patient by establishing a multidisciplinary working model in collaboration with the haematologist. This collaborative effort ensures the provision of personalised and specialised treatment. <h3>Conflict of Interest</h3> No conflict of interest